Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

FLIPI score, number of lines of treatment impact survival in follicular lymphoma patients

15 Aug 2020

Undergoing more lines of treatment and having a higher Follicular Lymphoma International Prognostic Index (FLIPI) score appear to be associated with worse survival in FL patients, a recent study has shown.

The study included 1,088 FL patients (median age, 57 years; 51 percent female), of whom 78 percent had FLIPI scores available upon diagnosis. A total of 208 deaths were observed. The overall survival (OS) rate was 92 percent at 5 years, 80 percent at 10 years, and 65 percent at 15 years. The median OS was not reached.

Stage I, II, and III malignancy had largely comparable 5-year OS rates, at 97 percent, 91 percent, and 88 percent, respectively. FLIPI score at baseline was also important. The 10-year OS rates for those with low, intermediate, and high baseline FLIPI were 91 percent, 77 percent, and 70 percent, respectively.

A total of 922 patients received treatment for FL, the most common of which was rituximab in combination with chemotherapy (52.1 percent) and chemotherapy alone (10.3 percent). Anthracycline was the most popular first-line treatment option, followed by rituximab monotherapy and radiation alone.

Patient outcomes deteriorated with increasing lines of treatment. Those who had received only first-line therapy did not reach median OS, while patients who had undergone second-line therapy showed a median OS of 11.67 years. By the fifth line of therapy, median OS had dropped to 3.13 years. At four or more lines of therapy, progression-free survival was only at 0.9 years.

“Future prospective studies are needed to assess a possible correlation between increased FLIPI score and inferior outcomes,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.